Scholarlink

Background <p>Parkinson’s disease (PD) is highly variable between patients, and regular assessments are needed to adjust symptomatic treatment. Wearable sensor measurements can complement clinical examinations and patient-reported outcome measures in the management of PD, but their clinical usefulness is yet to be established. Previous studies have described wearable sensor measurements from selected patients, often with advanced disease, but not PD patients in general. We sought to objectively describe daily-life movement characteristics of population-representative patients with PD using the wrist-worn Personal KinetiGraph (PKG), and to relate these sensor measurements to clinical data and proposed PKG-based treatment targets.</p> Methods <p>Individuals in a population-based random sample of patients with PD were evaluated with clinical assessments, patient-reported outcome measures and six-day PKG recordings. PKG outcomes included bradykinesia score (BKS) and dyskinesia score (DKS), reflecting symptom severity. Mortality within eight years was recorded.</p> Results <p>The study included 286 patients with a median age of 73 years and a median time since diagnosis of five years. Clinical and patient-reported variables expected to increase with disease or symptom severity were positively correlated with bradykinesia score (BKS) and negatively correlated with dyskinesia score (DKS). Patients with BKS &gt; 25 had lower levodopa-equivalent daily dose, higher self-reported symptom burden and lower health-related quality of life compared to patients with BKS ≤ 25. Age- and sex-adjusted mortality rates were 1.8 times higher in patients with BKS &gt; 25.</p> Conclusions <p>Sensor-based motor assessments with PKG reflect clinical outcome measures in population-representative PD patients. A high degree of sensor-assessed bradykinesia (BKS &gt; 25) at baseline was associated with higher mortality, shorter disease duration and less intensive treatment. The results suggest that high BKS is a risk factor for mortality, possibly as a marker of undertreatment.</p> Trial registration <p>ClinicalTrials.gov identifier NCT03130595, registration date 22 April 2017.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Wearable sensor measurements in relation to clinical characteristics and mortality in patients with Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月11日

查看全文
  • Daniel von Below,
  • Susanna M. Wallerstedt,
  • Filip Bergquist

摘要

Background

Parkinson’s disease (PD) is highly variable between patients, and regular assessments are needed to adjust symptomatic treatment. Wearable sensor measurements can complement clinical examinations and patient-reported outcome measures in the management of PD, but their clinical usefulness is yet to be established. Previous studies have described wearable sensor measurements from selected patients, often with advanced disease, but not PD patients in general. We sought to objectively describe daily-life movement characteristics of population-representative patients with PD using the wrist-worn Personal KinetiGraph (PKG), and to relate these sensor measurements to clinical data and proposed PKG-based treatment targets.

Methods

Individuals in a population-based random sample of patients with PD were evaluated with clinical assessments, patient-reported outcome measures and six-day PKG recordings. PKG outcomes included bradykinesia score (BKS) and dyskinesia score (DKS), reflecting symptom severity. Mortality within eight years was recorded.

Results

The study included 286 patients with a median age of 73 years and a median time since diagnosis of five years. Clinical and patient-reported variables expected to increase with disease or symptom severity were positively correlated with bradykinesia score (BKS) and negatively correlated with dyskinesia score (DKS). Patients with BKS > 25 had lower levodopa-equivalent daily dose, higher self-reported symptom burden and lower health-related quality of life compared to patients with BKS ≤ 25. Age- and sex-adjusted mortality rates were 1.8 times higher in patients with BKS > 25.

Conclusions

Sensor-based motor assessments with PKG reflect clinical outcome measures in population-representative PD patients. A high degree of sensor-assessed bradykinesia (BKS > 25) at baseline was associated with higher mortality, shorter disease duration and less intensive treatment. The results suggest that high BKS is a risk factor for mortality, possibly as a marker of undertreatment.

Trial registration

ClinicalTrials.gov identifier NCT03130595, registration date 22 April 2017.